임상시험에서 PD-1 및 PD-L1 억제제의 치료 관련 이상반응

Wang 등(목요일,)이 이 문제를 연구했습니다.

www.synapsesocial.com/papers/69d74dbdb54ccf0cfef30ce3 — DOI: https://doi.org/10.1001/jamaoncol.2019.0393

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Untitled· 2017 · 6 citations
2. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens· 2017 · 1,065 citations
3. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab· 2016 · 248 citations
4. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer· 2018 · 386 citations
5. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma· 2017 · 3,372 citations